Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CAP-CMV GmbH Raises New Funds to Further Develop its Novel hCMV Vaccine

Published: Tuesday, March 25, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
Company has also appointed Albrecht Läufer as its new CEO.

CAP-CMV GmbH has announced that it has raised in total € 1.7 m from its investors Peppermint Venture Partners (PVP), NRW.Bank, Creathor Venture, KfW and private investors in a combined seed/start-up investment.

The funds will be used to advance further it´s vaccine candidate, HCMV dense bodies (DBs) derived from CEVEC´s human CAP cell technology.

DBs contain highest amount of relevant antigens, and were shown to elicit strong and lasting humoral and cellular immune responses in preclinical models.

DBs are the ideal vaccine candidate to prevent hCMV caused diseases. Congenital infection with hCMV is a leading cause for neonatal disabilities. As up to 40% of the population carry this virus the hCMV infection is also a major health threat to recipients of solid organ or stem transplantations.

Wolfgang Kintzel, start-up CEO of CAP-CMV comments: “We are very happy that we could now secure our Series A financing round for this unique vaccine project. The money will be used to prove in various animal studies the clear advantages of our system against other technologies as well as advancing our pre-clinical programs.”

Also in March CAP-CMV´s shareholders appointed Albrecht Läufer as its new CEO. Joachim Rautter, Managing Partner at PVP, and speaker of CAP-CMV´s advisory board says: “Wolfgang has put CAP-CMV on the right track and we thank him for his tremendous efforts to establish the company. We now welcome Albrecht and wish him success in taking forward CAP-CMV on its growth path while Wolfgang will be appointed to the board of CAP-CMV”.

Albrecht Läufer was cofounder and first CEO of Vakzine Projekt Management GmbH (VPM), the company which has started preclinical development of HCMV dense bodies and then licensed the project to CAP-CMV.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
New Method of Cancer Immunotherapy
Stanford chemists have dicovered a new form of cancer immunotherapy using sugar presence manipulation.
Vortex Ring Freezing Applications
Accidental lab discovery could aid cell delivery and cell-free protein production.
Examining Immune Memory
Researchers investigate the 'storage/research for the future' functions of antibodies and understanding of B cells.
Expanding the Stable of Workhorse Yeasts
New genome sequences target the next generation of yeasts with improved biotechnology uses.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Blocking the Migration of Cancer Cells to Destroy Them
Scientists in Geneva developed an antibody able to fight off lymphomas.
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!